QIAGEN reports supervisory board member’s restricted stock unit vesting and share settlement

Qiagen ( (QGEN) ) has shared an announcement.

QIAGEN has disclosed a managers’ transaction involving supervisory board member Toralf Haag under European market abuse regulations, highlighting equity-based compensation practices at the company. Haag received the release of 5,990 restricted stock units (RSUs) from a 2025 grant and 3,166 RSUs from a 2023 grant, with an exercise price of $0 and a reference closing share price of $49.80 on February 27, 2026.

Following the vesting of these awards on February 28, 2026, Haag ultimately received 4,599 common shares via net share settlement, with a portion of the shares withheld by QIAGEN to cover taxes and transaction-related costs. The off-market transaction, categorized as linked to the exercise of share-based incentive programs, underlines the ongoing use of stock-based remuneration to align management and supervisory interests with shareholder value, while having a limited direct impact on the company’s overall capital structure.

The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

More about Qiagen

QIAGEN N.V. is a life sciences company headquartered in Venlo, Netherlands, whose shares are listed on regulated markets in Frankfurt and multiple other European exchanges as well as the NYSE and Swiss venues. The company focuses on molecular diagnostics, applied testing, academic research, and pharmaceutical development, providing sample and assay technologies and related products worldwide.

Average Trading Volume: 2,173,009

Technical Sentiment Signal: Strong Buy

Current Market Cap: $10.1B

See more data about QGEN stock on TipRanks’ Stock Analysis page.